Evidence map›Paper›PMID 35871355›Full record

ArticleJournal of Alzheimer's disease : JAD2022

Geriatricians' Perspectives on the Multiple Dimensions of Utility of Genetic Testing for Alzheimer's Disease: A Qualitative Study.

Jalayne J Arias, Grace A Lin, Ana M Tyler, Michael P Douglas, Kathryn A Phillips

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Communicating and Using Dementia Risk Evidence.Journal of Alzheimer's disease : JAD · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jalayne J AriasSchool of Public Health, Georgia State University, Atlanta, GA, USA.
Grace A LinDepartment of Internal Medicine, University of California, San Francisco, CA, USA.
Ana M TylerMemory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.
Michael P DouglasCenter for Translational and Policy Research on Precision Medicine, University of California, San Francisco, CA, USA.
Kathryn A PhillipsCenter for Translational and Policy Research on Precision Medicine, University of California, San Francisco, CA, USA.

Funding

BUILDING THE EVIDENCE BASE FOR APPROPRIATE AND EFFICIENT IMPLEMENTATION OF EMERGING GENOMIC TESTS FOR DISEASE MANAGEMENT AND SCREENINGR01HG011792 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PHILLIPS, KATHRYN A · 2021 to 2025
$4.6M
Coverage, Price, and Reimbursement for Multigene Tests for Cancer and Related ConditionsR01CA221870 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PHILLIPS, KATHRYN A · 2018 to 2020
$2.2M
Employment and Insurance Discrimination Based on Biomarkers for Alzheimer's diseaseK01AG057796 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ARIAS, JALAYNE J · 2018 to 2022
$652k
NCI NIH HHS R01 CA221870NHGRI NIH HHS R01 HG011792NIA NIH HHS K01 AG057796
6 · The paper itself

Abstract

backgroundResearch advancements in Alzheimer's disease (AD) raise opportunities for genetic testing to improve diagnostic and risk assessment. Despite emerging developments, it is unclear how geriatricians perceive the potential clinical and personal utility of genetic testing for their patients. Geriatricians' perspectives are essential to understanding potential ethical, policy, and clinical challenges.

objectiveIn this paper, we report on geriatricians' perspectives on the utility of genetic testing for AD.

methodsSemi-structured interviews with California geriatricians within different practices settings to collect and characterize their perspectives on genetic testing for AD. We used an adapted grounded theory approach to analyze recorded and transcribed interviews.

resultsWe identified geriatricians' (n = 10) perspectives on the clinical and personal utility of testing, alongside their views on clinical care approaches for older adults. Geriatricians perceived minimal clinical utility of genetic testing for AD, though that may change with the availability of disease-modifying therapies. Yet, they recognized the potential personal utility of testing (e.g., assisting with future financial planning). Finally, geriatricians expressed concerns regarding patients' anxiety from learning about genetic status, particularly through direct-to-consumer (DTC) testing.

conclusionOur data highlight that the decision to order genetic testing requires clinical and ethical considerations, including balancing limited clinical utility with the potential personal utility. Although DTC testing is available, geriatricians perceive that they have an important role in managing the decision to test and interpreting the results. Further research is needed to inform policy and ethical guidelines to support geriatricians' critical role to counsel patients considering clinical and DTC genetic testing.

Indexed as

Alzheimer DiseaseGeriatriciansAgedGenetic TestingHumansMoralsQualitative ResearchAlzheimer’s diseaseAPOEdirect-to-consumer testinggenetic testing

Identifiers

PMID35871355
PMCPMC9712158

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.